Synthesis and In Vitro Studies of a Gd(DOTA)–Porphyrin Conjugate for Combined MRI and Photodynamic Treatment - Archive ouverte HAL Access content directly
Journal Articles Inorganic Chemistry Year : 2020

Synthesis and In Vitro Studies of a Gd(DOTA)–Porphyrin Conjugate for Combined MRI and Photodynamic Treatment

Abstract

With the aim of developing new molecular theranostic agents, a π-extended Zn(II) porphyrin as photosensitizer for photodynamic therapy (PDT) linked to two GdDOTA-type complexes for magnetic resonance imaging (MRI) detection was synthesized. The relaxivity studies revealed a much higher relaxivity value per Gd ion for this medium sized molecule (19.32 mM–1 s–1 at 20 MHz and 298 K) compared to clinical contrast agents—a value which strongly increases in the presence of bovine serum albumin, reaching 25.22 mM–1 s–1. Moreover, the photophysical studies showed the strong ability of the molecule to absorb light in the deep red (670 nm, ε ≈ 60000 M–1 cm–1) and in the near-infrared following two-photon excitation (920 nm, σ2 ≈ 650 GM). The conjugate is also able to generate singlet oxygen, with a quantum yield of 0.58 in DMSO. Promising results were obtained in cellular studies, demonstrating that the conjugate is internalized in HeLa cells at micromolar concentration and leads to 70% of cell death following 30 min irradiation at 660 nm. These results confirm the potential of the designed molecule as an imaging and therapeutic agent.
Fichier principal
Vignette du fichier
JENNI_Inorg Chem.pdf (1.55 Mo) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

hal-03011644 , version 1 (18-11-2020)

Identifiers

Cite

Sébastien Jenni, Celia ́ Bonnet, Frédéric Bolze, Agnes A. Pallier, Angélique Sour, et al.. Synthesis and In Vitro Studies of a Gd(DOTA)–Porphyrin Conjugate for Combined MRI and Photodynamic Treatment. Inorganic Chemistry, 2020, 59 (19), pp.14389-14398. ⟨10.1021/acs.inorgchem.0c02189⟩. ⟨hal-03011644⟩
73 View
121 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More